• ABOUT US
    ▼
    • Our Vision
    • Leadership Team
  • OUR RESEARCH
    ▼
    • Our Approach
    • Publications
    • Conferences
  • PROGRAMS
    ▼
    • Pipeline
    • VIS171
    • VIS513
  • FOR PATIENTS
    ▼
    • Clinical Trials
  • CAREERS
    ▼
    • Open Positions & Benefits
    • Our Culture
    • Co-op program
  • Contact

Visterra

We Bring Better Biologics to Life

  • ABOUT US
    • Our Vision
    • Leadership Team
  • OUR RESEARCH
    • Our Approach
    • Publications
    • Conferences
  • PROGRAMS
    • Pipeline
    • VIS171
    • VIS513
  • FOR PATIENTS
    • Clinical Trials
  • CAREERS
    • Open Positions & Benefits
    • Our Culture
    • Co-op program
  • Contact

Sibeprenlimab for Patients With IgA Nephropathy: Results From a Prespecified Interim Analysis of the Phase 3 VISIONARY Study

June 6, 2025 | 62nd ERA Congress
Vlado Perkovic, et al.

Sibeprenlimab for Patients With IgA Nephropathy: Results From a Prespecified Interim Analysis of the Phase 3 VISIONARY Study

Vlado Perkovic, Jonathan Barratt, Richard Lafayette, Adrian Liew, Yusuke Suzuki, Kevin Carroll, Chee Kay Cheung, Vladimir Tesař, Hernán Trimarchi, Muh Geot Wong, Hong Zhang, Dana V Rizk

>SEE PRESENTATION

© 2025 Visterra, Inc. Terms of usePrivacy PolicySite Design: Fassino/Design

We use cookies on our website to see how you interact with it. By accepting, you agree to our use of such cookies. Privacy PolicyOk